Phenotypic and molecular analyses of primary lateral sclerosis
Authors:
- Hiroshi MitsumotoHMHiroshi Mitsumoto
- Peter L. NagyPNPeter L. Nagy
- Chris GenningsCGChris Gennings
- Jennifer MurphyJMJennifer Murphy
- Howard AndrewsHAHoward Andrews
- Raymond GoetzRGRaymond Goetz
- Mary Kay FloeterMFMary Kay Floeter
- Jonathan HupfJHJonathan Hupf
- Jessica SingletonJSJessica Singleton
- Richard J. BarohnRBRichard J. Barohn
- Sharon NationsSNSharon Nations
- Christen ShoesmithCSChristen Shoesmith
Open Access
- 1 June 2015
- journal article
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 1 (1) , e3
Abstract
Objective: To understand phenotypic and molecular characteristics of patients with clinically “definite” primary lateral sclerosis (PLS) in a prospective study. Methods: Six sites enrolled 41 patients who had pure upper motor neuron dysfunction, bulbar symptoms, a normal EMG done within 12 months of enrollment, and onset of symptoms ≥5 years before enrollment. For phenotypic analyses, 27 demographic, clinical, and cognitive variables were analyzed using the k-means clustering method. For molecular studies, 34 available DNA samples were tested for the C9ORF72 mutation, and exome sequencing was performed to exclude other neurologic diseases with known genetic cause. Results: K-means clustering using the 25 patients with complete datasets suggested that patients with PLS can be classified into 2 groups based on clinical variables, namely dysphagia, objective bulbar signs, and urinary urgency. Secondary analyses performed in all 41 patients and including only variables with complete data corroborated the results from the primary analysis. We found no evidence that neurocognitive variables are important in classifying patients with PLS. Molecular studies identified C9ORF72 expansion in one patient. Well-characterized pathogenic mutations were identified in SPG7, DCTN1, and PARK2. Most cases showed no known relevant mutations. Conclusions: Cluster analyses based on clinical variables indicated at least 2 subgroups of clinically definite PLS. Molecular analyses further identified 4 cases with mutations associated with amyotrophic lateral sclerosis, Parkinson disease, and possibly hereditary spastic paraplegia. Phenotypic and molecular characterization is the first step in investigating biological clues toward the definition of PLS. Further studies with larger numbers of patients are essential.Keywords
This publication has 37 references indexed in Scilit:
- Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutationsBMC Genomic Data, 2013
- Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathyBrain, 2012
- Predicting the Functional Effect of Amino Acid Substitutions and IndelsPLOS ONE, 2012
- Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD)Muscle & Nerve, 2012
- Copy number variation detection and genotyping from exome sequence dataGenome Research, 2012
- MSV3d: database of human MisSense variants mapped to 3D protein structureDatabase: The Journal of Biological Databases and Curation, 2012
- A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTDNeuron, 2011
- A map of human genome variation from population-scale sequencingNature, 2010
- Characterization of DCTN1 genetic variability in neurodegenerationNeurology, 2009
- R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutationMovement Disorders, 2006